Skip to main content

Advertisement

Download PDF

Laundering CNV data for candidate process prioritization in brain disorders

Molecular Cytogenetics volume 12, Article number: 54 (2019) Cite this article

Abstract

Background

Prioritization of genomic data has become a useful tool for uncovering the phenotypic effect of genetic variations (e.g. copy number variations or CNV) and disease mechanisms. Due to the complexity, brain disorders represent a major focus of genomic research aimed at revealing pathologic significance of genomic changes leading to brain dysfunction. Here, we propose a “CNV data laundering” algorithm based on filtering and prioritizing of genomic pathways retrieved from available databases for uncovering altered molecular pathways in brain disorders. The algorithm comprises seven consecutive steps of processing individual CNV data sets. First, the data are compared to in-house and web databases to discriminate recurrent non-pathogenic variants. Second, the CNV pool is confined to the genes predominantly expressed in the brain. Third, intergenic interactions are used for filtering causative CNV. Fourth, a network of interconnected elements specific for an individual genome variation set is created. Fifth, ontologic data (pathways/functions) are attributed to clusters of network elements. Sixth, the pathways are prioritized according to the significance of elements affected by CNV. Seventh, prioritized pathways are clustered according to the ontologies.

Results

The algorithm was applied to 191 CNV data sets obtained from children with brain disorders (intellectual disability and autism spectrum disorders) by SNP array molecular karyotyping. “CNV data laundering” has identified 13 pathway clusters (39 processes/475 genes) implicated in the phenotypic manifestations.

Conclusions

Elucidating altered molecular pathways in brain disorders, the algorithm may be used for uncovering disease mechanisms and genotype-phenotype correlations. These opportunities are strongly required for developing therapeutic strategies in devastating neuropsychiatric diseases.

Background

Brain disorders frequently result from genomic variations altering a variety of molecular and cellular pathways [1]. Due to a significant overlap between genetic variations associated with phenotypic spectrum of various disorders, psychiatric genetic research may be focused on interactomes (networks of interacting genes/proteins) influencing certain pathways. This is further supported by the findings indicating an increase of total burden of rare, inherited or de novo copy number variations (CNVs) to be associated with psychiatric disorders [2], suggesting that different malfunctioning genes might be involved in the same biological process, disruption of which causes the disease. Protein-protein interaction (PPI) networks (molecular pathways) seem to be a more reliable drug target than gene mutations or CNV per se. Indeed, molecular pathways to intellectual disability (ID), autism spectrum disorders (ASD) and schizophrenia are repeatedly reported to be based on specific PPIs [1, 3]. The convergent pathways include, but are not limited to, those regulating neurogenesis, neuronal migration, synaptic functions, transcription, translation, cell cycle and programmed cell death [1, 4]. The majority of the networks altered in brain diseases regulate either processes crucial for neural development and functioning or those influencing cell cycle and communication. Particularly, RhoGTPase pathway is involved in nervous system development, dendritic spines formation and neuronal differentiation [5]; Ras/RAP pathway is responsible for long term potentiation of AMPA receptors (Ras) and long term depression (Rap) [6]. Cell cycle pathway may be altered to produce genome instability leading to cancer or neurodegenerative diseases [7]. More precisely, ERK/PI3K signaling pathway influences the more general pathway regulating the cell cycle and cell differentiation and is altered in neurodevelopmental diseases [8]. Wnt signaling pathway takes part in neuronal migration, dendrite and synapse formation, as well as axon guidance [9]. However, the alterations to these pathways are rarely addressed in the CNV context, probably due to the lack of appropriate bioinformatic algorithms [10, 11]. Here, we propose an algorithm for “laundering” CNV data based on a previously described bioinformatic technique for CNV prioritization [12]. The algorithm may be applicable for identifying causative (candidate) processes for brain disorders in diagnostic and basic research.

Methods

We propose a CNV prioritization algorithm — “data laundering” — suitable both for diagnostic and basic research. The algorithm is based on an idea that brain diseases result from genomic alterations affecting directly the brain [13, 14] and, consequently, predominant expression of a gene in the central nervous system increases the probability of its contribution to a neurobehavioral phenotype [12]. We designate the algorithm as “laundering” because of the resemblance to machine-washing (each step processes the data from the previous stage to be filtered several times using different criteria). Figure 1 schematically outlines the procedure.

Fig. 1
figure1

Data laundering algorithm for CNV prioritization

Full size image

First, a pool of CNVs is obtained by molecular karyotyping. At this stage, CNVs are checked for recurrence by in-house and web databases. In-house databases of genomic variants obtained by similar microarray types are applied to spot recurrent aberrations. It is to note that the indexation of CNV in a Database of Genomic Variants or any other database dedicated to non-pathogenic genome variations is not a criterion for the exclusion at following stages. Further, the localization and ontology of CNV genes (e.g. using UCSC genome browser, NCBI gene, OMIM, PubMed etc.) are obtained. At this stage, genes lacking appropriate ontology, CNV encompassing introns, recurrent/non-pathogenic CNV are excluded from further analysis. It is worth mentioning that here, CNV are defined as copy number DNA gains/losses < 500 kbp.

Secondly, the genes are in silico analyzed in terms of the expression in the central nervous system. As brain pathology is suggested to be mainly associated with neurobehavioral phenotypes, it is recommended to proceed to the next step with a pool of genes highly expressed in the brain.

Third step is referred to as retrieving gene-gene interactions. Considering the differences in databases, it is suggested to use several resources (e.g. NCBI gene, BioGRID, STRING). Here, we have merged data from NCBI gene, BioGRID and STRING.

During the fourth step, the gene list is evaluated for uncovering interactions and interaction enriched gene clusters (sets of interacting genes). Further, only large groups of interacting genes are analyzed, leaving aside small clusters of interacting elements. This criterion is based on a hypothesis that highly interacting genes (proteins) are more likely to be involved in the same processes or influence a disease with similar symptoms [15].

Fifth, the pathway lists are obtained for the set of interacting genes. During database selection, one should consider such parameters as the nature and curability of pathway data. Here, Gene Ontology (GO), KEGG, Reactome, NCBI Biosystems were used.

Sixth, to process the pathway lists, we introduce a parameter (prioritization criterion) to determine significantly enriched pathways. To calculate the parameter, a total number of genes for each pathway are obtained. Pathways, in which less than 25 genes are affected by CNVs, are excluded. The remaining pathways are ranked using the index of pathway prioritization (IPP):

$$ {I}_{PP}=\frac{\sum {N}_{CNV\ genes}}{\sum {N}_{pathway\ genes}} $$

where IPP — index of pathway prioritization; NCNV genes — number of CNV genes in a pathway found in molecularly karyotyped cohort; Npathway genes — total number of pathway genes. If the IPP is higher than average (i.e. evaluated by three sigma rule), the pathway is prioritized.

Seventh, ontologies attributed to the elements of prioritized pathways are considered; pathways are clustered according to the involvement in shared networks (cascades of processes) [16]. Thus, the algorithm provides a set of enriched processes (clusters of pathways) in a disease or in an individual patient.

Using the algorithm and Affymetrix CytoScan HD microarray, we analyzed 191 genomes (DNA isolated from peripheral blood) of children with ID, ASD and congenital abnormalities without gross chromosomal and genomic rearrangements (i.e only the CNVs less than 500 kbp in size were included). The raw results of the algorithm processing are shown in Fig. 2.

Fig. 2
figure2

Intermediate results before pathway clustering

Full size image

Results

We obtained a set of 741 genes affected by pathogenic or likely pathogenic CNVs. “Expression filtering” allowed to select 307 genes highly expressed in the brain. Cross-checking interactions of these genes (step 3) was used for building an interactome (step 4) encompassing 3156 genes. These genes were involved in 302, 978, 3380, and 2350 pathways, according to KEGG, REACTOME, Biosystems, and GO, respectively. For each pathway, we calculated IPP, which allowed us to obtain enriched pathways for each database: KEGG — 1, REACTOME — 11, Biosystems — 0, GO — 27. Pathway clustering was performed according to pathway ontologies.

The application of CNV prioritization or “data laundering” algorithm yielded 39 genomic networks (pathways) forming 13 clusters of processes, involving 475 genes. These pathway clusters were as follows: neurodegenerative diseases, proteasome, signaling by ERBB4, transcription regulation, regulation of TP53, signaling by NOTCH, senescence, mitosis, DNA repair, vesicles functioning, actin functioning, macromolecular interactions, B cells functioning (Table 1).

Table 1 Pathways organized by clusters
Full size table

Discussion

According to the value of Ipp, the most significant pathways clusters were “proteasome”, “neurodegenerative diseases”, “regulation of TP53”, “vesicles functioning”, “signaling by NOTCH”, “actin functioning”. Proteasome cluster was the most enriched one. Alterations to the proteasome complexes decrease proteolytic activity leading to the accumulation of damaged or structurally abnormal proteins. Similar protein accumulation may underlie neurodegenerative, cardiovascular and autoimmune diseases [17]. Neurodegenerative diseases cluster was enriched in genes associated with several devastative diseases and implicated in a variety of molecular/cellular processes. More precisely, CDK5 is involved in synaptic plasticity and neuronal migration; DCTN1 takes part in the formation of mitotic spindle and axons; FUS regulates gene expression and maintains the integrity of the genome; GRN regulates cell growth, and OPTN participates in membrane transport [18]. The p53-pathway consists of genes that respond to a wide range of stress signals. Stress responses include apoptosis, cellular senescence and cell cycle arrest. In addition, p53-regulated genes may produce proteins that transmit stress signals to neighboring cells and. These genes are involved in DNA reparation, regulation of p53 and binding to signaling pathways [19]. Disruption of synaptic vesicles is associated with developmental disorders. The fusion of synaptic vesicles with a presynaptic plasma membrane, followed by the release of a neurotransmitter, is essential for the neural transmission [20]. The proteins belonging to the SNARE complex (Synaptic-soluble N-ethylmaleimide-sensitive factor attachment receptor) participate in the majority of membrane-vesicles fusion events. A number of diseases are associated with mutations in the genes of this complex; for example, homozygous mutations of SNAP29 leading to impaired endocytic recycling and cell motility has been associated with CEDNIK syndrome (cerebral dysgenesis, nervous system disorders, ichthyosis and palmar-plantar keratodermia) [21]. Additionally, a decrease of SNAP25 was found in the hippocampus of patients with schizophrenia. A single nucleotide polymorphism (SNP) in SNAP25 was associated with hyperactivity in ASD. In high-functioning autism, increased syntaxin 1A expression was observed. Various studies showed that the reduced expression in the anterior part of the cingulate gyrus was observed in patients with ASD [22]. Notch signaling plays a significant role in embryonic development and dendritic development. In mammals, deletions of the Notch signal modulator (Numb) disrupted the maturation of neurons in the developing cerebellum, and violated axon branching in sensory ganglia [23]. The dysfunction of the signaling pathways that reorganize synaptic actin is associated with a variety of brain development abnormalities, including ASD, schizophrenia and ID. Indeed, genes such as SHANK3, GIT1, DISC1, SRGAP3, OPHN1, LIMK1, NRG1, CYFIP1, SYNGAP1, KALRN, NCKAP1 and CNKSR2 regulate upward signaling that stimulate the dynamics of the actin cytoskeleton in dendritic spines [24].

Currently, individual genome analysis obtains big data which are to be processed for basic, diagnostic and therapeutic purposes. Molecular karyotyping detects CNVs, which may output candidate gene and pathway lists. To discover genetic basis of an individual’s phenotype or pathways to a disorder, it appears necessary to answer two questions:

  1. 1.

    What are the pathways disrupted by CNV genes?

  2. 2.

    Do these pathways merge into a single global cluster reflecting a specific cellular/molecular process?

Application of bioinformatic strategies similar to the data laundering algorithm is able to answer these questions. It is necessary to stress that data analysis requires tools considering multiple factors and a theoretic background. Pathway clustering represents a promising bioinformatic tool, enabling the development of therapeutic strategies based on a molecular mechanism [25]. Similarly, our algorithm may be used as for an individual, particularly, as for a disease, as a whole. Furthermore, “data laundering” method is based on freely available web tools.

Conclusion

The algorithm has been applied to a cohort of 191 children with ID, ASD and congenital abnormalities, yielding 13 pathway clusters potentially associated with brain disorders: neurodegenerative diseases, proteasome, signaling by ERBB4, transcription regulation, regulation of TP53, signaling by NOTCH, senescence, mitosis, DNA repair, vesicles functioning, actin functioning, macromolecular interactions, B cells functioning. Thus, the data laundering algorithm using CNV data allows obtaining clusters of candidate (disease-associated) processes. This algorithm is important for further basic and diagnostic research. Moreover, the application of the algorithm to molecular diagnostics of genomic pathology makes it possible to expand our knowledge about disease mechanisms in individual cases. Our findings may have importance for the development of therapeutic strategies and relevant psychological intervention for genetically determined ID and ASD cases caused by CNVs [26,27,28]. Molecular pathways are key elements of etiological concepts in brain disorders, significantly contributing to our understanding of neurological and psychiatric diseases. To determine disease mechanisms, one has to uncover the molecular and cellular pathways in addition determining a gene or chromosome abnormality underlying the condition. In other words, the main task for such studies is to find disrupted biological processes, which should be properly reflected in common disease description [29,30,31,32]. The application of our algorithm can lead to successful identification of molecular and cellular mechanisms for brain diseases for developing personalized therapeutic strategies.

Availability of data and materials

The datasets used and analyzed during the current study are available at http://dekanat.bsu.edu.ru/f.php/1/disser/case/filedisser/filedisser/998_dissertaciya_zelenova.pdf

Abbreviations

ADHD:

Attention deficit hyperactivity disorder

ASD:

Autism spectrum disorder

CNV:

Copy number variation

DNA:

Deoxyribonucleic acid

GO:

Gene Ontology

GTP:

Guanosine triphosphate

ID:

Intellectual disability

PPI:

Protein-protein interaction

RNA:

Ribonucleic acid

SNP:

Single nucleotide polymorphism

References

  1. 1.

    Parikshak NN, Gandal MJ, Geschwind DH. Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat Rev Genet. 2015;16(8):441–58.

  2. 2.

    Takumi T, Tamada K. CNV biology in neurodevelopmental disorders. Curr Opin Neurobiol. 2018;48:183–92.

  3. 3.

    Willsey AJ, Morris MT, Wang S, et al. The psychiatric cell map initiative: a convergent systems biological approach to illuminating key molecular pathways in neuropsychiatric disorders. Cell. 2018;174(3):505–20.

  4. 4.

    Vorsanova SG, Yurov YB, Iourov IY. Neurogenomic pathway of autism spectrum disorders: linking germline and somatic mutations to genetic-environmental interactions. Curr Bioinform. 2017;12(1):19–26.

  5. 5.

    Huang GH, Sun ZL, Li HJ, Feng DF. Rho GTPase-activating proteins: regulators of rho GTPase activity in neuronal development and CNS diseases. Mol Cell Neurosci. 2017;80:18–31.

  6. 6.

    Zhang L, Zhang P, Wang G, Zhang H, Zhang Y, Yu Y, et al. Ras and Rap signal bidirectional synaptic plasticity via distinct subcellular microdomains. Neuron. 2018;98(4):783–800.e4.

  7. 7.

    Iourov IY, Vorsanova SG, Liehr T, Kolotii AD, Yurov YB. Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain. Hum Mol Genet. 2009;18(14):2656–69.

  8. 8.

    Levitt P, Campbell DB. The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J Clin Invest. 2009;119(4):747–54.

  9. 9.

    Cristino AS, Williams SM, Hawi Z, et al. Neurodevelopmental and neuropsychiatric disorders represent an interconnected molecular system. Mol Psychiatry. 2014;19(3):294–301.

  10. 10.

    Iourov IY, Vorsanova SG, Zelenova MA, Korostelev SA, Yurov YB. Genomic copy number variation affecting genes involved in the cell cycle pathway: implications for somatic mosaicism. Int J Genomics. 2015;2015:757680.

  11. 11.

    Dharanipragada P, Vogeti S, Parekh N. iCopyDAV: integrated platform for copy number variations-detection, annotation and visualization. PLoS One. 2018;13(4):e0195334.

  12. 12.

    Iourov IY, Vorsanova SG, Yurov YB. In silico molecular cytogenetics: a bioinformatic approach to prioritization of candidate genes and copy number variations for basic and clinical genome research. Mol Cytogenet. 2014;7:98.

  13. 13.

    Kingsbury MA, Yung YC, Peterson SE, Westra JW, Chun J. Aneuploidy in the normal and diseased brain. Cell Mol Life Sci. 2006;63(22):2626–41.

  14. 14.

    Iourov IY, Vorsanova SG, Yurov YB. Chromosomal variation in mammalian neuronal cells: known facts and attractive hypotheses. Int Rev Cytol. 2006;249:143–91.

  15. 15.

    Huttlin EL, Bruckner RJ, Paulo JA, et al. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545(7655):505–9.

  16. 16.

    Yurov YB, Vorsanova SG, Iourov IY. Network-based classification of molecular cytogenetic data. Curr Bioinform. 2017;12(1):27–33.

  17. 17.

    Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta. 2014;1843(1):13–25.

  18. 18.

    Morello G, Guarnaccia M, Spampinato AG, La Cognata V, D’Agata V, Cavallaro S. Copy number variations in amyotrophic lateral sclerosis: piecing the mosaic tiles together through a systems biology approach. Mol Neurobiol. 2018;55(2):1299–322.

  19. 19.

    Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28):3943–56.

  20. 20.

    Chen J, Yu S, Fu Y, Li X. Synaptic proteins and receptors defects in autism spectrum disorders. Front Cell Neurosci. 2014;8:276.

  21. 21.

    Rapaport D, Lugassy Y, Sprecher E, Horowitz M. Loss of SNAP29 impairs endocytic recycling and cell motility. PLoS One. 2010;5:e9759.

  22. 22.

    Ramakrishnan NA, Drescher MJ, Drescher DG. The SNARE complex in neuronal and sensory cells. Mol Cell Neurosci. 2012;50(1):58–69.

  23. 23.

    Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci. 2005;8(6):709–15.

  24. 24.

    Yan Z, Kim E, Datta D. Synaptic actin dysregulation, a convergent mechanism of mental disorders? J Neurosci. 2016;36(45):11411–7.

  25. 25.

    Iourov IY, Vorsanova SG, Voinova VY, Yurov YB. 3p22.1p21.31 microdeletion identifies CCK as Asperger syndrome candidate gene and shows the way for therapeutic strategies in chromosome imbalances. Mol Cytogenet. 2015;8:82.

  26. 26.

    Iourov IY, Vorsanova SG, Zelenova MA, Vasin KS, Kurinnaia OS, Korostelev SA, Yurov YB. Structural variations of the genome in autistic spectrum disorders with intellectual disability. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(7):50–4.

  27. 27.

    Benger M, Kinali M, Mazarakis ND. Autism spectrum disorder: prospects for treatment using gene therapy. Mol Autism. 2018;9:39.

  28. 28.

    Iourov IY, Zelenova MA, Vorsanova SG, Voinova VV, Yurov YB. 4q21.2q21.3 duplication: molecular and neuropsychological aspects. Curr Genomics. 2018;19(3):173–8.

  29. 29.

    Heng HH, Horne SD, Chaudhry S, Regan SM, Liu G, Abdallah BY, Ye CJ. A Postgenomic perspective on molecular Cytogenetics. Curr Genomics. 2018;19(3):227–39.

  30. 30.

    Iourov IY. Cytogenomic bioinformatics: practical issues. Curr Bioinform. 2019;14(5):372–3.

  31. 31.

    Iourov IY, Vorsanova SG, Yurov YB. Pathway-based classification of genetic diseases. Mol Cytogenet. 2019;12:4.

  32. 32.

    Mi Z, Guo B, Yin Z, Li J, Zheng Z. Disease classification via gene network integrating modules and pathways. R Soc Open Sci. 2019;6(7):190214.

Download references

Acknowledgements

Authors thank Alexey A. Mikryukov from VNIIOFI (Moscow, Russia) for help in computational analysis.

Funding

Our study has been partially supported by RFBR and CITMA according to the research project No. 18–515-34005. Prof. SG Vorsanova is supported by the Government Assignment of the Russian Ministry of Health, Assignment no. AAAA-A18–118051590122-7. Prof. IY Iourov is supported by the Government Assignment of the Russian Ministry of Science and Higher Education, Assignment no. AAAA-A19–119040490101-6.

Author information

Affiliations

  1. Mental Health Research Center, Russia, Moscow, 115522
    • Maria A. Zelenova
    • , Yuri B. Yurov
    • , Svetlana G. Vorsanova
    •  & Ivan Y. Iourov
  2. Academician Yu.E. Veltishchev Research Clinical Institute of Pediatrics, N.I, Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Russia, Moscow, 125635
    • Maria A. Zelenova
    • , Yuri B. Yurov
    • , Svetlana G. Vorsanova
    •  & Ivan Y. Iourov
Authors
  1. Maria A. Zelenova
    View author publications
    You can also search for this author in
  2. Yuri B. Yurov
    View author publications
    You can also search for this author in
  3. Svetlana G. Vorsanova
    View author publications
    You can also search for this author in
  4. Ivan Y. Iourov
    View author publications
    You can also search for this author in

Contributions

MAZ wrote the manuscript and performed bioinformatic analyses; YBY provided data and made significant theoretical input; SGV provided data and made significant theoretical input; IYI wrote the manuscript, performed bioinformatic analyses made significant theoretical input. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ivan Y. Iourov.

Ethics declarations

Ethics approval and consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zelenova, M.A., Yurov, Y.B., Vorsanova, S.G. et al. Laundering CNV data for candidate process prioritization in brain disorders. Mol Cytogenet 12, 54 (2019). https://doi.org/10.1186/s13039-019-0468-7

Download citation

Keywords

  • Autism
  • Bioinformatics
  • Brain
  • CNV
  • Intellectual disability
  • Pathways

Molecular Cytogenetics

ISSN: 1755-8166